638 related articles for article (PubMed ID: 31928404)
41. Immunocytochemical localization of estrogen and progesterone receptors (ER & PgR) in breast cancer.
Fukushima H; Matsuda M; Kawakami H; Kudo A; Kuroki Y; Sakurai M; Shohji T; Nagashima Y; Asami M; Hanaoka T
Okajimas Folia Anat Jpn; 1995 Mar; 71(6):365-70. PubMed ID: 7739846
[TBL] [Abstract][Full Text] [Related]
42. [Studies on estrogen and progesterone receptors in human breast cancer by sucrose gradient centrifugation (author's transl)].
Iino Y
Nihon Naibunpi Gakkai Zasshi; 1979 Aug; 55(8):971-93. PubMed ID: 488478
[TBL] [Abstract][Full Text] [Related]
43. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B; Kane JL; Valente AL; van Laar R; Gallagher C; Shriver CD; Ellsworth RE
Ann Surg Oncol; 2013 Jan; 20(1):87-93. PubMed ID: 22875649
[TBL] [Abstract][Full Text] [Related]
44. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
45. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
46. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
47. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
48. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
49. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
50. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
51. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
52. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
53. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
Vollenweider-Zerargui L; Barrelet L; Wong Y; Lemarchand-Béraud T; Gómez F
Cancer; 1986 Mar; 57(6):1171-80. PubMed ID: 3943040
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
55. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.
Elledge RM; Ciocca DR; Langone G; McGuire WL
Cancer; 1993 Apr; 71(8):2499-506. PubMed ID: 8095853
[TBL] [Abstract][Full Text] [Related]
56. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
57. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
[TBL] [Abstract][Full Text] [Related]
58. Differentiated expression of estrogen receptors (ER) and progesterone receptors (PgR) in ductal breast cancers.
Wojnar A; Drozdz K; Podhorska-Okołów M; Pudełko M; Szuba A; Zabel M; Dziegiel P
Folia Histochem Cytobiol; 2009; 47(1):55-60. PubMed ID: 19419938
[TBL] [Abstract][Full Text] [Related]
59. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.
Reiner A; Neumeister B; Spona J; Reiner G; Schemper M; Jakesz R
Cancer Res; 1990 Nov; 50(21):7057-61. PubMed ID: 2208173
[TBL] [Abstract][Full Text] [Related]
60. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.
Cohen DA; Dabbs DJ; Cooper KL; Amin M; Jones TE; Jones MW; Chivukula M; Trucco GA; Bhargava R
Am J Clin Pathol; 2012 Dec; 138(6):796-802. PubMed ID: 23161712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]